Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

NCT02688608 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Anaplastic Thyroid Cancer

Interventions

DRUG: Pembrolizumab

Sponsor

Saad A Khan

Collaborators

[object Object]